Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) dropped by -2.72 or -2.46 points during the last session to $87.95 per share. One of the highlights of the day was the net money flow figure, which stood at $14.2 million even as the stock accepted $25.5 million in upticks but rejected $11.3 million in downticks. The up/down ratio for the last observation was a 2.26. The 1-week percentage change for the stock price is registered at -3.87%.A block transaction occurred with $20.58 million in upticks and $5.09 million in downticks while the up/down ratio was calculated to be 4.04. The stock witnessed a net inflow of $15.49 million at the end of the block trade.
Vertex Pharmaceuticals Incorporated has dropped 5.2% in the last five trading days, however, the shares have posted positive gains of 6.14% in the last 4 weeks. Vertex Pharmaceuticals Incorporated is up 5.1% in the last 3-month period. Year-to-Date the stock performance stands at -31.07%.
Currently the company Insiders own 1.8% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.03% . Institutional Investors own 97.01% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%. . On the companys insider trading activities, The director, of Vertex Pharmaceuticals Inc / Ma, Boger Joshua S had unloaded 5,130 shares at $91.18 per share in a transaction on June 15, 2016. The total value of transaction was $467,753. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) witnessed a decline in the market cap on Friday as its shares dropped 4.07% or 3.68 points. After the session commenced at $90.46, the stock reached the higher end at $91.24 while it hit a low of $85.88. With the volume soaring to 2,658,851 shares, the last trade was called at $86.73. The company has a 52-week high of $143.45. The company has a market cap of $21,453 million and there are 247,349,860 shares in outstanding. The 52-week low of the share price is $75.9.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.